Healthcare Industry News: FluMist
News Release - September 3, 2008
MAP Pharmaceuticals Appoints Alan H. Cohen, M.D., as Vice President, Clinical Development and Medical Affairs, Pulmonary
MOUNTAIN VIEW, Calif., Sept. 3 (HSMN NewsFeed) -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP ) today announced the appointment of Alan H. Cohen, M.D., FAAP, FCCP, to the position of Vice President, Clinical Development and Medical Affairs, Pulmonary.In his new role, Dr. Cohen will oversee development and execution of MAP Pharmaceuticals' pediatric asthma clinical program, including Phase 3 clinical trials for Unit Dose Budesonide (UDB). Dr. Cohen will direct the initiation, execution and evaluation of clinical trials and lead clinical interactions with global regulatory authorities. Dr. Cohen will report to Donald Kellerman, Pharm.D., Senior Vice President, Clinical Development and Medical Affairs.
Dr. Cohen brings more than 20 years of therapeutic, clinical and medical experience, with specific expertise in the field of pediatric pulmonology -- including asthma, chronic obstructive pulmonary disease and cystic fibrosis. Most recently, Dr. Cohen was Chief Medical Officer and Vice President of Global Medical Affairs, Safety & Pharmacovigilance at Jazz Pharmaceuticals, Inc., where he was actively involved in all levels of clinical research, from pre-clinical work through Phase 4 development. He built the department of medical affairs, overseeing all aspects of his team, including investigator initiated trials, medical education, field-based medical affairs, advisory boards as well as safety and pharmacovigilance. Prior to his tenure at Jazz Pharmaceuticals, Dr. Cohen was Senior Director of Medical Affairs at MedImmune, Inc., where he played a central role in brand support for their respiratory products, including Synagis®, FluMist® and RespiGam(TM). He has also worked in private practice as a pediatric pulmonologist, affiliated with Emory University, Morehouse School of Medicine and Scottish Rite Children's Medical Center, in Atlanta, GA.
"Alan's ability to oversee all stages of the drug development process from clinical trial development to support of marketed products, coupled with his passion for pediatric medicine, makes him an ideal addition to our team as we move towards our goal of commercializing UDB," said Timothy S. Nelson, President and Chief Executive Officer of MAP Pharmaceuticals. "The perspective he brings, both as an accomplished clinician and academic, adds to an already strong UDB team."
Dr. Cohen remains clinically active in the field of pediatric pulmonology, and he currently serves as an Adjunct Clinical Instructor of Pediatrics at the Stanford University School of Medicine, Lucile Packard Children's Hospital, caring for patients and helping to teach physicians in training. He previously was an Adjunct Assistant Professor at Johns Hopkins University School of Medicine and Assistant Professor of Pediatrics, as well as co-director of the Pediatric Lung Transplant program at the Washington University School of Medicine, St. Louis Children's Hospital.
Dr. Cohen has authored and published over 100 peer reviewed articles, abstracts, platform presentations and book chapters in his areas of expertise, and he has lectured extensively throughout the world. He has previously served as a manuscript reviewer for both the Journal of Pediatrics and CHEST, the journal of the American College of Chest Physicians.
Dr. Cohen received his Bachelor of Science and Bachelor of Arts from the University of Rochester and his medical degree from New York Medical College. He completed his residency and fellowship training in Pediatrics and Pediatric Pulmonology, respectively, at the University of Colorado School of Medicine and the National Jewish Center for Immunology and Respiratory Disease.
About MAP Pharmaceuticals, Inc.
MAP Pharmaceuticals develops and plans to commercialize new therapies for children and adults who suffer from chronic conditions that it believes are not adequately treated by currently available medicines. The company applies its proprietary inhalation technologies to enhance the therapeutic benefits and commercial attractiveness of proven drugs while minimizing risk by capitalizing on their known safety, efficacy and commercialization history. MAP Pharmaceuticals has two drug candidates in Phase 3 clinical trials. Unit Dose Budesonide is being developed for the potential treatment of pediatric asthma, and MAP0004 is being developed for the potential treatment of migraine. MAP Pharmaceuticals' pipeline also includes a drug candidate in early clinical development for the treatment of asthma and chronic obstructive pulmonary disease.
Additional information about MAP Pharmaceuticals can be found at http://www.mappharma.com.
Forward-Looking Statements
In addition to statements of historical facts or statements of current conditions, this press release contains forward-looking statements, including with respect to MAP Pharmaceuticals' UDB product candidate in clinical development. Actual results may differ materially from current expectations based on risks and uncertainties affecting MAP Pharmaceuticals' business, including, without limitation, risks and uncertainties relating to the development, clinical testing and potential commercialization of UDB. The reader is cautioned not to unduly rely on the forward-looking statements contained in this press release. MAP Pharmaceuticals expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law. Additional information on potential factors that could affect MAP Pharmaceuticals' results and other risks and uncertainties are detailed in its Quarterly Report on Form 10-Q, filed with the SEC on August 13, 2008, and available at http://edgar.sec.gov.
Source: MAP Pharmaceuticals
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
